I think the company in general is in very good shape, but there are some general investor concerns about how long Stryker can maintain its 20-plus percent growth in earnings operational rate.

Getting European Commission approval is a key step ... but the fact that there has been such a disconnect between the takeout price of $76 (per Guidant share) and the current share price tells you there's more uncertainty and nervousness out there than normal.

If you don't invest in R&D, you're going to get left behind, because all the other companies are doing it.

Early on, treating (sleep apnea) was largely a lifestyle issue because people were falling asleep in the day and this would help them feel better.

All the while the company's done a good job of maintaining strong gross margins in a tough reimbursement market like the U.S.. That means they're controlling costs well on the manufacturing side, which isn't an easy thing to do.

If you would be loved, love, and be loveable